Yang Ying-Zi
Department of Oncology, Dianjiang Country Hospital of Traditional Chinese Medicine, Chongqing 408300. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):84-8. doi: 10.7534/j.issn.1009-2137.2016.01.016.
To investigate the clinical efficacy and safety between CHOPE regimen alone and it combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma.
Eighty patients with relapsed and refractory non-Hodgkin's B cell lymphoma were chosen in our hospital from January 2009 to June 2012, and randomly were divided into 2 groups including the CHOPE regimen group (40 patients) and CHOPE plus thalidomide group (40 patients); and the clinical efficacy, the levels of sVEGF and LDH before and after treatment, the survival rate and the III-IV degree toxic side-effects in these 2 groups were compared.
The clinical efficacy of CHOPE+thalidomide group was significant higher than that of CHOPE group alone (P < 0.05). The levels of sVEGF and LDH after treatment in the CHOPE+thalidomide group was significantly higher than that in CHOPE group alone before treatment (P < 0.05). The survival rate in CHOPE+thalidomide group was significant higher than that in CHOPE group alone (P < 0.05). The median survival time in CHOPE+thalidomide group was significant longer than that in CHOPE group alone (P < 0.05). The incidence of III-IV degree toxic side effects was not significantly different between 2 these groups (P > 0.05).
Compared with CHOPE regimen alone, CHOPE regimen combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma can efficiently delay the disease progression, reduce tumor burden level, enhance the long-term survival rate, morever did not increase the risk of toxic side effects.
